FrancophonIA/ELRC3.0 huggingface dataset:
English: The effect of age was evaluated in a population pharmacokinetic analysis on plasma migalastat clearance in the ERT-naïve study population.
Spanish: El efecto de la edad fue evaluado en un análisis farmacocinético de la población sobre el aclaramiento plasmático de migalastat en pacientes no expuestos previamente a TSE.
English: Pack size of 14 capsules.
Spanish: Envase de 14 cápsulas.
English: Size 2 hard capsule (6.4x18.0 mm) with an opaque blue cap and opaque white body with “A1001” printed in black, containing white to pale brown powder.
Spanish: Cápsula dura de tamaño 2 (6,4 x 18,0 mm) con extremo azul opaco y cuerpo blanco opaco con la impresión «A1001» en negro que contiene un polvo de blanco a marrón claro.
English: (95% CI: -3.636, 1.575; n=18) in the ERT group.
Spanish: (IC del 95 %: -3,636, 1,575; n=18) en el grupo de TSE.
English: Do not take Galafold if you:
Spanish: No tome Galafold:
English: No clinically significant differences in LVMi were observed during the initial 6-month placebo-controlled period.
Spanish: No se observaron diferencias clínicamente significativas en el IMVI durante el periodo controlado con placebo de 6 meses inicial.
English: Migalastat is not a substrate for MDR1 or BCRP, nor is it an inhibitor of BCRP, MDR1, or BSEP human efflux transporters.
Spanish: Migalastat no es un sustrato de MDR1 o BCRP, ni tampoco un inhibidor de transportadores de eflujos en humanos BCRP, MDR1 o BSEP.
English: Fabry disease is a progressive X-linked lysosomal storage disorder which affects males and females.
Spanish: La enfermedad de Fabry es un trastorno por almacenamiento lisosómico progresivo ligado al cromosoma X, que afecta a hombres y mujeres.
English: Galafold is not intended for concomitant use with enzyme replacement therapy (see section 4.4).
Spanish: Galafold no está indicado para un uso simultáneo con la terapia de sustitución enzimática (ver sección 4.4).
English: PRESS and hold tab at the left 2.
Spanish: PRESIONAR la lengüeta a la izquierda 2.
English: Once in lysosomes dissociation of migalastat restores -Gal A activity, leading to the catabolism of GL-3 and related substrates.
Spanish: Una vez en los lisosomas, la disociación de migalastat restablece la actividad de la -Gal A, lo que conduce al catabolismo de la GL-3 y los sustratos relacionados.
English: On your first day of taking this medicine from a new blister sleeve, record the date on the blister sleeve.
Spanish: El primer día que comience con este medicamento, marque la fecha en el blíster.
English: (95% CI: -1.89, 0.40; n=41).
Spanish: (IC del 95 %: -1,89, 0,40; n=41).
English: Swallow the capsule whole.
Spanish: Tragar las cápsulas enteras.
English: Protein sequence change
Spanish: Secuencia proteica modificada
English: Each capsule contains migalastat hydrochloride equivalent to 123 mg migalastat.
Spanish: Cada cápsula contiene clorhidrato de migalastat equivalente a 123 mg de migalastat.
English: You should not take Galafold if you are also receiving enzyme replacement therapy.
Spanish: No debe tomar Galafold si también está utilizando terapia de sustitución enzimática.
English: Take Galafold capsule every other day and punch out the perforated circle on the blister sleeve on the days you are not taking Galafold.
Spanish: Tomar la cápsula de Galafold en días alternos y perforar el círculo blanco en el blíster los días que no se toma Galafold.
English: Patient-Reported Outcome - Gastrointestinal Symptoms Rating Scale In the ERT-naïve trial, analyses of the Gastrointestinal Symptoms Rating Scale demonstrated that treatment with Galafold was associated with statistically significant (p<0.05) improvements versus placebo from baseline to month 6 in the diarrhoea domain, and in the reflux domain for patients with symptoms at baseline.
Spanish: Resultados reportados por los pacientes - Escala de evaluación de síntomas gastrointestinales En el ensayo en pacientes no expuestos previamente a TSE, los análisis de la escala de evaluación de síntomas gastrointestinales demostraron que el tratamiento con Galafold estaba asociado a mejoras estadísticamente significativas (p<0,05) comparado con el placebo desde el periodo basal hasta el mes 6 en el ámbito de la diarrea, y del reflujo en pacientes con síntomas en el periodo basal.
English: Galafold should not be taken on 2 consecutive days.
Spanish: Galafold no se debe tomar durante 2 días consecutivos.
English: Galafold has no or negligible influence on the ability to drive and use machines.
Spanish: La influencia de Galafold sobre la capacidad para conducir y utilizar máquinas es nula o insignificante.
English: If you forget to take your capsule at the usual time but remember later, you can take the capsule only if it is within 12 hours of your normal dosing time.
Spanish: Si olvidó tomar la cápsula a la hora habitual y se acordó posteriormente se puede tomar la cápsula solamente si está dentro del intervalo de las 12 horas siguientes a la hora habitual a la que se toma la dosis.
English: In a single dose study with Galafold in non-Fabry subjects with varying degrees of renal insufficiency, exposures were increased by 4.3-fold in subjects with severe renal impairment (GFR < 30 mL/min/1.73 m
Spanish: En un estudio de dosis única con Galafold en sujetos sin la enfermedad de Fabry con diferentes grados de insuficiencia renal, las exposiciones aumentaron de 4,3 veces en sujetos con insuficiencia renal grave (TFG< 30 ml/min/1,73 m
English: UNKNOWN (E66_Y123del; del Exon2)
Spanish: DESCONOCIDO (E66_Y123del; del Exon2)
English: Galafold is not intended for concomitant use with enzyme replacement therapy.
Spanish: Galafold no está indicado para un uso concomitante con la terapia de sustitución enzimática.
English: If you stop taking Galafold Do not stop taking this medicine without talking to your doctor.
Spanish: Si interrumpe el tratamiento con Galafold No debe interrumpir el tratamiento sin hablar antes con su médico.
English: In the ERT-experienced trial, plasma lyso-Gb3 levels slightly increased but remained low in patients with amenable mutations treated with Galafold for the 30 month duration of the study.
Spanish: En el ensayo en pacientes previamente tratados con TSE, los niveles plasmáticos de lyso-Gb3 aumentaron ligeramente pero permanecieron bajos en los pacientes con mutaciones susceptibles de responder al tratamiento tratados con Galafold durante los 30 meses que duró el estudio.
English: The first Phase 3 trial (ATTRACT) was a randomised open-label active comparator trial that evaluated the efficacy and safety of Galafold compared to enzyme replacement therapy (ERT) (agalsidase beta, agalsidase alfa) in 52 male and female patients with Fabry disease who were receiving ERT prior to trial entry and who have amenable mutations (ERT-experienced trial).
Spanish: El primer ensayo de fase 3 (ATTRACT) fue un ensayo de comparador activo, abierto, aleatorizado, que evaluó la eficacia y la seguridad del Galafold comparado con la terapia de sustitución enzimática (TSE) (agalsidasa beta, agalsidasa alfa) en 52 pacientes varones y mujeres con la enfermedad de Fabry en tratamiento con TSE antes de ser incluidos en el ensayo y portadores de mutaciones susceptibles de responder al tratamiento (ensayo en pacientes previamente tratados con TSE).
English: Left Ventricular Mass Index (LVMi)
Spanish: Índice de masa ventricular izquierda (IMVI)
English: Marketing Authorisation Holder Amicus Therapeutics Europe Limited Block 1, Blanchardstown Corporate Park Ballycoolen Road
Spanish: Titular de la autorización de comercialización Amicus Therapeutics Europe Limited Block 1, Blanchardstown Corporate Park Ballycoolen Road
English: Blood Creatine Phosphokinase increased
Spanish: Aumento de la creatinfosfoquinasa en sangre Peso aumentado
English: It is not yet known if this medicine affects fertility in men.
Spanish: No se sabe si este medicamento afecta a la fertilidad masculina.
English: During the first period (18-months) ERT-experienced patients were randomised to switch from ERT to Galafold or continue with ERT.
Spanish: En el primero (de 18 meses), pacientes previamente tratados con TSE se aleatorizaron a cambiar la TSE por Galafold o a continuar con la TSE.
English: • Muscle pain (myalgia)
Spanish: • Dolores musculares (mialgia)
English: In the ERT-experienced trial, following 18 months of treatment with Galafold there was a statistically significant decrease in LVMi (p< 0.05).
Spanish: En el ensayo en pacientes previamente tratados con TSE, después de 18 meses de tratamiento con Galafold se produjo una reducción estadísticamente significativa del IMVI (p< 0,05).
English: UNKNOWN (E66_Y123del; del Exon2?)
Spanish: DESCONOCIDO (E66_Y123del; del Exon2?)
English: Each capsule contains migalastat hydrochloride equivalent to 123 mg migalastat
Spanish: Cada cápsula contiene clorhidrato de migalastat equivalente a 123 mg de migalastat
English: Paraesthesia Dizziness Hypoaesthesia
Spanish: Parestesia Mareos Hipoestesia
English: What Galafold looks like and contents of the pack Opaque, blue, and white hard capsules, marked with “A1001” in black ink, containing white to pale brown powder.
Spanish: Cápsulas duras azules y blancas opacas marcadas con «A1001» en tinta negra, que contienen un polvo de blanco a marrón claro.
English: The second Phase 3 trial (FACETS) was a 6-month randomised double-blind placebo-controlled trial (through month 6) with an 18-month open-label period to evaluate the efficacy and safety of Galafold in 50 male and female patients with Fabry disease who were naïve to ERT, or had previously been on ERT and had stopped for at least 6 months and who have amenable mutations (ERT-naïve trial).
Spanish: El segundo ensayo de fase 3 (FACETS) fue un ensayo controlado con placebo, doble ciego, aleatorizado, de 6 meses (hasta el sexto mes), con un periodo abierto de 18 meses, para evaluar la eficacia y la seguridad de Galafold en 50 pacientes varones y mujeres con la enfermedad de Fabry sin exposición previa a TSE, o que habían sido tratados anteriormente con TSE y lo habían interrumpido durante al menos 6 meses, y portadores de mutaciones susceptibles de responder al tratamiento (ensayo con pacientes no expuestos previamente a TSE).
English: The second OLE trial (AT1001-042) included patients that both transferred from OLE study AT1001-041 and directly from Phase 3 study ATTRACT, and is ongoing.Renal Function
Spanish: El segundo ensayo de extensión abierto (AT1001-042) incluyó a pacientes provenientes tanto del estudio de extensión abierto AT1001-041 como directamente del estudio de fase 3 ATTRACT, y aún está en curso.
English: Hepatic impairment No dosage adjustment of Galafold is required in patients with hepatic impairment (see section 5.2).
Spanish: Insuficiencia hepática No se requiere un ajuste de dosis de Galafold en pacientes con insuficiencia hepática (ver sección 5.2).
English: Do not take this medicine if you are breast-feeding, until you have spoken with your doctor, pharmacist, or nurse.
Spanish: No tome este medicamento si está dando el pecho a su hijo hasta que haya consultado con su médico, farmacéutico o enfermero.
English: In the ERT- naïve trial, Galafold showed statistically significant reductions in plasma lyso-Gb3 concentrations and kidney interstitial capillary GL-3 inclusions in patients with amenable mutations.
Spanish: En el ensayo con pacientes no expuestos previamente a TSE, Galafold mostró reducciones estadísticamente significativas en las concentraciones plasmáticas de lyso-Gb3 y en las inclusiones de GL-3 por capilar intersticial renal en pacientes con mutaciones susceptibles de responder al tratamiento.
English: Galafold is not indicated for use in patients with non-amenable mutations (see section 5.1).
Spanish: Galafold no está indicado en pacientes con mutaciones no susceptibles de responder al tratamiento (ver sección 5.1).
English: Your doctor will monitor your condition and whether your medicine is working every 6 months while you are taking Galafold.
Spanish: Mientras esté tomando Galafold, su médico debe valorar su estado y si su medicamento está funcionando cada 6 meses.
English: C]-migalastat hydrochloride in the concentration range between 1 and
Spanish: C]-migalastat en el rango de concentración entre 1 y 100 M.
English: Patients randomised to placebo in Stage 1 and switched to Galafold at month 6 (Stage 2) also demonstrated statistically significant decreases in interstitial capillary GL-3 inclusions at month 12 (-0.33±0.15; -58%) (p=0.014).
Spanish: Los pacientes elegidos al azar para utilizar placebo en la fase 1 y que cambiaron a Galafold en el mes 6 (fase 2) también demostraron descensos estadísticamente significativos en las inclusiones de GL-3 por capilar intersticial en el mes 12 (-0,33±0,15; -58%) (p=0,014).
English: It is not yet known whether this medicine passes into breast milk.
Spanish: No se sabe si este medicamento se excreta en la leche materna.
English: While taking Galafold you should use effective birth control.
Spanish: Mientras esté tomando Galafold debe utilizar un método anticonceptivo.
English: Disease Substrate
Spanish: Sustrato de la enfermedad
English: c.760-762delGTT or c.761-763del c.760_762delGTT or c.761_763del p.V254del
Spanish: I253S c.760-762delGTT o c.761-763del c.760_762delGTT o c.761_763del p.V254del c.769G>C
English: Patients randomised to Galafold in Stage 1 demonstrated statistically significant greater reduction (±SEM) in mean interstitial capillary GL-3 deposition (-0.25±0.10; -39%) at month 6 compared to placebo (+0.07 ± 0.13; +14%) (p=0.008).
Spanish: Los pacientes elegidos al azar para el uso de Galafold en la fase 1 demostraron una mayor reducción estadísticamente significativa (±SEM) en la deposición de GL-3 por capilar intersticial promedio (-0,25±0,10; -39 %) en el mes 6 comparado con el placebo (+0,07 ± 0,13; +14 %) (p=0,008).
English: c.A1C or c.A1T
Spanish: c.A1C o c.A1T
English: In the ERT-experienced trial, renal function remained stable for up to 18 months of treatment with Galafold.
Spanish: En el ensayo en pacientes previamente tratados con TSE, la función renal permaneció estable hasta los 18 meses de tratamiento con Galafold.
English: c.A1023C or c.A1023T
Spanish: c.A1023C o c.A1023T
English: c.1196G>A or c.1197G>A c.G1196A or c.G1197A
Spanish: c.1196G>A o c.1197G>A c.G1196A o c.G1197A
English: See package leaflet for further instructions.
Spanish: Para más instrucciones consultar el prospecto.
English: c.1019G>A or c.1020G>A c.G1019A or c.G1020A
Spanish: c.1019G>A o c.1020G>A c.G1019A o c.G1020A
English: c.T148C or c.C150G or c.C150A F50L
Spanish: c.T148C o c.C150G o c.C150A F50L
English: Protein Sequence change c.1A>C or c.1A>T
Spanish: Secuencia proteica modificada c.1A>C o c.1A>T
English: Table 3: Mutations not amenable to Galafold (migalastat)
Spanish: Tabla 3: Tabla de no susceptibilidad a Galafold (migalastat)
English: g.6736_11545del c.370-533_c.1290+277del
Spanish: Secuencia proteica modificada g.6736_11545del c.370-533_c.1290+277del
English: c.G561T or c.G561A or c.G561C M187I
Spanish: c.G561T o c.G561A o c.G561C M187I
English: After an average of 3.4 years of treatment, the mean annualised rate of change in eGFRCKD-EPI was -0.74 mL/min/1.73 m
Spanish: Tras una media de 3,4 años de tratamiento, la tasa de cambio medio anualizada de la TFG estimada CKD-EPI fue de -0,74 ml/min/1,73 m
English: C]-migalastat hydrochloride revealed that approximately 77% of the radiolabeled dose was recovered in urine of which 55% of was excreted as unchanged migalastat and 4% as combined metabolites M1, M2 and M3.
Spanish: Un ensayo farmacocinético en voluntarios varones sanos con 150 mg de clorhidrato de C]-migalastat reveló que aproximadamente el 77% de la dosis radiomarcada se recuperó en orina, de la cual el 55% se excretó como migalastat inalterado y el 4% como los metabolitos combinados M1, M2 y M3.
English: c.G153A or c.G153T or c.G153C M51I
Spanish: c.G153A o c.G153T o c.G153C M51I
English: This medicine has not been studied in children and adolescents under the age of 16 years; therefore, the safety and efficacy in this age group has not been established.
Spanish: Este medicamento no ha sido estudiado en niños menores de 16 años.
English: c.A712C or c.T714A or c.T714G S238R
Spanish: c.A712C o c.T714A o c.T714G S238R
English: c.G611A or G612A
Spanish: c.G611A o G612A
English: c.T337C or c.T339A or c.T339G F113L
Spanish: c.T337C o c.T339A o c.T339G F113L
English: In the ERT- naïve trial and open-label extension, renal function remained stable for up to 5 years of treatment with Galafold.
Spanish: En el ensayo de extensión abierto con pacientes no expuestos previamente a TSE, la función renal permaneció estable durante un máximo de 5 años de tratamiento con Galafold.
English: If more than 12 hours has passed the patient should resume taking Galafold at the next planned dosing day and time according to the every other day dosing schedule.
Spanish: Si han transcurrido más de 12 horas, el paciente debe volver a tomar Galafold el día correspondiente a la siguiente dosis y a la hora habitual, de acuerdo con la pauta posológica de días alternos.
English: c.A504C or c.A504T
Spanish: c.A504C o c.A504T
English: c.T1147C or c.C1149G or c.C1149A
Spanish: c.T1147C o c.C1149G o c.C1149A
English: c.T817C or c.T819A or c.T819G F273L
Spanish: c.T817C o c.T819A o c.T819G F273L
English: c.1046G>A or c.1047G>A c.G1046A or c.G1047A
Spanish: c.1046G>A o c.1047G>A c.G1046A o c.G1047A
English: c.[253G>A; 254G>T; 255T>G] c.G253A/G254T/T255G
Spanish: Secuencia proteica modificada c.[253G>A; 254G>T; 255T>G] c.G253A/G254T/T255G
English: c.712A>C or c.714T>A or c.714T>G
Spanish: c.712A>C o c.714T>A o c.714T>G
English: c.611G>A or 612G>A
Spanish: c.611G>A o 612G>A
English: c.A924T or c.A924C
Spanish: c.A924T o c.A924C
English: Mean annualised rate of change in eGFRCKD-EPI was -0.40 mL/min/1.73 m
Spanish: La tasa de cambio medio anualizada en la TFG estimada CKD-EPI fue de -0,40 ml/min/1,73 m
English: c.3G>A or c.3G>T or c.3G>C c.G3A or c.G3T or c.G3C
Spanish: c.3G>A o c.3G>T o c.3G>C c.G3A o c.G3T o c.G3C
English: c.140G>A or 141G>A
Spanish: c.140G>A o 141G>A
English: c.A442C or c.T444A or c.T444G S148R
Spanish: c.A442C o c.T444A o c.T444G S148R
English: (95% CI: -2.653, -0.782; n=31).
Spanish: (IC del 95 %: -2,653, -0,782;
English: c.1023A >C or c.1023A>T
Spanish: c.1023A >C o c.1023A>T
English: 1.478; n=34) in the Galafold group compared to -1.03 mL/min/1.73 m
Spanish: (IC del 95 %: -2,272, 1,478; n=34) en el grupo de Galafold comparado con -1,03 ml/min/1,73 m
English: BLISTER SLEEVE
Spanish: LÁMINA DE BLÍSTER
English: c.442A>C or c.444T>A or c.444T>G
Spanish: c.442A>C o c.444T>A o c.444T>G
English: c.216G>A or c.216G>T or c.216G>C
Spanish: c.216G>A o c.216G>T o c.216G>C
English: c.G126A or c.G126C or c.G126T M42I
Spanish: c.G126A o c.G126C o c.G126T M42I
English: c.T139C or c.T139A
Spanish: c.T139C o c.T139A
English: c.C816A or c.C816G
Spanish: c.C816A o c.C816G
English: After follow up in the OLE, the mean change from baseline in LVMi at Month 36 was -8.3 (95% CI: -17.1, 0.4; n=25) and at Month 48 was -9.1 (95% CI: -20.3, 2.0; n=18).
Spanish: Tras seguimiento en el ensayo de extensión abierto, el cambio promedio desde el periodo basal en el IMVI en el mes 36 fue de -8,3 (IC del 95 %: -17,1, 0,4; n=25) y en el mes 48 fue de -9,1 (IC del 95 %: -20,3, 2,0; n=18).
English: c.C159G or c.C159A
Spanish: c.C159G o c.C159A
English: UNKNOWN (del Exon3 and 4?)
Spanish: DESCONOCIDO (del Exon3 y 4?)
English: c.504A>C or c.504A>T
Spanish: c.504A>C o c.504A>T
English: c.148T>C or c.150C>G or c.150C>A
Spanish: c.148T>C o c.150C>G o c.150C>A
English: c.1147T>C or c.1149C>G or c.1149C>A
Spanish: c.1147T>C o c.1149C>G o c.1149C>A
English: c.G216A or c.G216T or c.G216C M72I
Spanish: c.G216A o c.G216T o c.G216C M72I
English: c.561G>T or c.561G>A or c.561G>C
Spanish: c.561G>T o c.561G>A o c.561G>C
English: c.139T>C or c.139T>A
Spanish: c.139T>C o c.139T>A
English: c.A124C or c.A124T
Spanish: c.A124C o c.A124T
English: c.G140A or G141A
Spanish: c.G140A o G141A
English: In the ERT-naïve trial, Galafold resulted in a statistically significant decrease in LVMi (p< 0.05); the mean change from baseline in LVMi at Month 18 to 24 was -7.7 (95% CI: -15.4, -0.01; n=27).
Spanish: En el ensayo en pacientes no expuestos previamente a TSE, Galafold produjo un descenso estadísticamente significativo del IMVI (p< 0,05); el cambio promedio desde el periodo basal en el IMVI en los meses de 18 a 24 fue de -7,7 (IC del 95 %: -15,4, -0,01; n=27).
English: Torticollis Pain in extremity
Spanish: Dolor en las extremidades
English: c.G284A or c.G285A
Spanish: c.G284A o c.G285A
English: c.G870A or c.G870C or c.G870T M290I
Spanish: c.G870A o c.G870C o c.G870T M290I
English: Table 2: Galafold (migalastat) amenability table
Spanish: Tabla 2: Tabla de susceptibilidad a Galafold (migalastat)
English: c.G412A or c.G412C
Spanish: c.G412A o c.G412C
English: c.G228C or c.G228A or c.G228T M76I
Spanish: c.G228C o c.G228A o c.G228T M76I
English: c.C519A or c.C519G
Spanish: c.C519A o c.C519G
English: c.280T>A or c.281G>C
Spanish: c.280T>A o c.281G>C
English: c.T241C or c.T241A
Spanish: c.T241C o c.T241A
English: c.924A>T or c.924A>C
Spanish: c.924A>T o c.924A>C
English: c.C233G or c.C233A
Spanish: c.C233G o c.C233A
English: c.159C>G or c.159C>A
Spanish: c.159C>G o c.159C>A
English: c.817T>C or c.819T>A or c.819T>G
Spanish: c.817T>C o c.819T>A o c.819T>G
English: c.C279G or c.C279A
Spanish: c.C279G o c.C279A
English: c.T881G or c.T881A
Spanish: c.T881G o c.T881A
English: c.412G>A or c.412G>C
Spanish: c.412G>A o c.412G>C
English: Fatigue Pain
Spanish: Fatiga Dolor
English: c.153G>A or c.153G>T or c.153G>C
Spanish: c.153G>A o c.153G>T o c.153G>C
English: c.G982A or c.G982C
Spanish: c.G982A o c.G982C
English: c.228G>C or c.228G>A or c.228G>T
Spanish: c.228G>C o c.228G>A o c.228G>T
English: (paraesthesia)
Spanish: (epistaxis)
English: c.G540C or c.G540T
Spanish: c.G540C o c.G540T
English: c.T187A or c.G188C
Spanish: c.T187A o c.G188C
English: c.C525G or c.C525A
Spanish: c.C525G o c.C525A
English: c.G261C or c.G261T
Spanish: c.G261C o c.G261T
English: c.G103C or c.G103A
Spanish: c.G103C o c.G103A
English: c.187T>A or c.188G>C
Spanish: c.187T>A o c.188G>C
English: c.G612T or c.G612C
Spanish: c.G612T o c.G612C
English: c.C207A or c.C207G
Spanish: c.C207A o c.C207G
English: c.T166A or c.G167C
Spanish: c.T166A o c.G167C
English: c.261G>C or c.261G>T
Spanish: c.261G>C o c.261G>T
English: c.G242A or c.G243A
Spanish: c.G242A o c.G243A
English: c.G285T or c.G285C
Spanish: c.G285T o c.G285C
English: c.G471C or c.G471T
Spanish: c.G471C o c.G471T
English: c.284G>A or c.285G>A
Spanish: c.284G>A o c.285G>A
English: c.G131A or c.G132A
Spanish: c.G131A o c.G132A
English: c.552T>A or c.552T>G
Spanish: c.552T>A o c.552T>G
English: c.337T>C or c.339T>A or c.339T>G
Spanish: c.337T>C o c.339T>A o c.339T>G
English: c.285G>T or c.285G>C
Spanish: c.285G>T o c.285G>C
English: c.C305G or c.C305A
Spanish: c.C305G o c.C305A
English: c.124A>C or c.124A>T
Spanish: c.124A>C o c.124A>T
English: c.241T>C or c.241T>A
Spanish: c.241T>C o c.241T>A
English: Galafold is not recommended for use in patients with severe renal insufficiency, defined as estimated GFR less than 30 mL/min/1.73m
Spanish: Galafold no está recomendado en pacientes con insuficiencia renal grave, con una TFG estimada inferior a 30 ml/min/1,73m
English: c.242G>A or c.243G>A
Spanish: c.242G>A o c.243G>A
English: Galafold is to be taken every other day.
Spanish: Galafold se debe tomar en días alternos.
English: c.519C>A or c.519C>G
Spanish: c.519C>A o c.519C>G
English: c.G734A or c.G735A
Spanish: c.G734A o c.G735A
English: c.G132T or c.G132C
Spanish: c.G132T o c.G132C
English: c.207C>A or c.207C>G
Spanish: c.207C>A o c.207C>G
English: c.C747G or c.C747A
Spanish: c.C747G o c.C747A
English: c.G888A or c.G888T or c.G888C M296I
Spanish: c.G888A o c.G888T o c.G888C M296I
English: Galafold has not been studied in patients with Fabry disease who have a GFR less than 30 mL/min/1.73 m2.
Spanish: Galafold no ha sido estudiado en pacientes con la enfermedad de Fabry portadores de una TFG estimada inferior a 30 ml/min/1,73 m2.
English: c.T258G or c.T258A
Spanish: c.T258G o c.T258A
English: c.471G>C or c.471G>T
Spanish: c.471G>C o c.471G>T
English: c.G1081A or c.G1081C
Spanish: c.G1081A o c.G1081C